Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated August 01, 2026, titled "Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015".
Dr. Reddy's Laboratories Ltd. Press Release Aug 01 2026
Filed with NSE · · 4 pages · English
Watch Dr. Reddy's Laboratories' latest callDr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call · Replay · Oct 23Read the transcript of Dr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings CallRelease
Dr. Reddy's Laboratories Ltd. on 6ix
Earlier from Dr. Reddy's Laboratories
- Dr. Reddy's Laboratories Ltd. Press Release Jul 23 2026
- Dr. Reddy's Laboratories Ltd. Press Release Jul 13 2026
- Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F
- Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
- Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)
Later from Dr. Reddy's Laboratories
- Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
- Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 07, 2026, titled "Intimation of Earnings call".
- Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Dr. Reddy s Receives DCGI Approval for Zytorvi® (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India.".
Follow Dr. Reddy's Laboratories into a list and get an email when it puts out news.
Follow Dr. Reddy's Laboratories